Explore All 789 Divestiture Life Science Deals - Search the Database Free
M&A Deal Summary |
|
|---|---|
| Date | June 6, 2011 |
| Target | TenX BioPharma - Monoclonal Antibody Cancer Therapy |
| Sector | Life Science |
| Buyer(s) | Emergent BioSolutions |
| Sellers(s) | TenX BioPharma |
| Deal Type | Divestiture |
| Deal Value | 6M USD |
FILTER BY
| Category | Company |
|---|---|
| Founded | 1998 |
| Sector | Healthcare Services |
| Employees | 900 |
| Revenue | 1.0B USD (2024) |
Emergent BioSolutions is a specialty biopharmaceutical company seeking to protect and enhance life by offering specialized products to healthcare providers and governments to address medical needs and emerging health threats. Emergent BioSolutions was founded in 1998 and is based in Gaithersburg, Maryland.
| Deal Context for Buyer | # |
|---|---|
| Overall | 5 of 11 |
| Sector: Life Science | 3 of 7 |
| Type: Divestiture | 3 of 6 |
| Country: United States | 5 of 7 |
| Year: 2011 | 1 of 1 |
| Size (of disclosed) | 7 of 7 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2010-10-28 |
Trubion Pharmaceuticals
Seattle, Washington, United States Trubion provides promising clinical-stage therapeutic candidates in the targeted disease areas of oncology and autoimmunity. |
Buy | $136M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-08-02 |
Bracco - Healthcare Protective Products Division
United States Bracco - Healthcare Protective Products Division includes the RSDL® (decontamination lotion) product that is cleared for marketing by the U.S. Food and Drug Administration (FDA) for removal or neutralization of chemical warfare agents from the skin, diversifies and broadens Emergent’s biodefense franchise into the chemical countermeasure market |
Buy | $26M |
| Category | Company |
|---|---|
| Founded | 2009 |
| Sector | Life Science |
TenX BioPharma, Inc. the rights to zanolimumab, an investigational, late-stage monoclonal antibody cancer therapy targeting T-cell lymphomas.
| Deal Context for Seller | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science | 1 of 1 |
| Type: Divestiture | 1 of 1 |
| Country: United States | 1 of 1 |
| Year: 2011 | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
